Cordis Endovascular's vena cava filter gets FDA go-ahead:
This article was originally published in Clinica
Cordis Endovascular, a Johnson & Johnson company, has received US FDA 510(k) clearance to market its 6F TRAPEASE permanent vena cava filter. Designed to prevent pulmonary embolism, the 6 French delivery system provides flexibility and support, minimising patient trauma and insertion site thrombosis. It has a symmetrical double-basket design, providing two levels of filtering and is the smallest, least invasive permanent vena cava filter available, claims the Warren, New Jersey-based company.